Alendronic acid

Identification

Name
Alendronic acid
Accession Number
DB00630
Description

Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's diseaseLabel1,5. It functions by preventing resorption of boneLabel1.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 249.096
Monoisotopic: 249.016724799
Chemical Formula
C4H13NO7P2
Synonyms
  • (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
  • (4-amino-1-hydroxybutylidene)bisphosphonic acid
  • 4-amino-1-hydroxybutane-1,1-diphosphonic acid
  • ABDP
  • Acide Alendronique
  • Acido Alendronico
  • Acidum Alendronicum
  • Alendronate
  • Alendronic acid
External IDs
  • G 704650
  • GTH 4
  • L 670
  • L 670452
  • MK 217

Pharmacology

Indication

Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of boneLabel1,2. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/minLabel.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Alendronic acid tablets have a very low oral bioavialabilityLabel2. After administration it distributes into soft tissue and bone or is excreted in the urineLabel. Alendronic acid does not undergo metabolismLabel.

Mechanism of action

Alendronic acid binds to bone hydroxyapatiteLabel. Bone resorption causes local acidification, releasing alendronic acid which is that taken into osteoclasts by fluid-phase endocytosis1. Endocytic vesicles are acidified, releasing alendronic acid to the cytosol of osteoclasts where they induce apoptosis1. Inhibition of osteoclasts results in decreased bone resorption which is shown through decreased urinary calcium, deoxypyridinoline and cross-linked N-telopeptidases of type I collagenLabel.

TargetActionsOrganism
AFarnesyl pyrophosphate synthase
inhibitor
Humans
AHydroxylapatite
antagonist
Humans
UTyrosine-protein phosphatase non-receptor type 4
inhibitor
Humans
UReceptor-type tyrosine-protein phosphatase S
inhibitor
Humans
UReceptor-type tyrosine-protein phosphatase epsilon
inhibitor
Humans
UV-type proton ATPase catalytic subunit A
inhibitor
Humans
Absorption

Mean oral bioavailability of alendronic acid in women is 0.64% and in men is 0.59%Label2. Bioavailability of alendronic acid decreases by up to 40% if it is taken within an hour of a mealLabel.

Volume of distribution

28LLabel.

Protein binding

78%Label. Studies in rats show that plasma protein binding increases with decreasing alendronic acid plasma concentration3 and increasing pH4.

Metabolism

Urinary excretion is the sole method of elimination of alendronic acid and no metabolites are detected upon urine collection2.

Route of elimination

Administration of radiolabeled alendronic acid results in 50% recovery in urine within 72 hoursLabel4. No alendronic acid is recovered in the fecesLabel2,3. Men excrete less alendronic acid than women, though race and advanced age do not affect eliminationLabel.

Half-life

Due to alendronic acid being incorporated into the skeleton, the terminal half life is estimated to be over 10 yearsLabel.

Clearance

71mL/minLabel.

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

In clinical studies, ≥3% of patients experience abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, musculoskeletal pain, and nauseaLabel.

No information for treatment of overdose is available, however patients should be given milk or antacids to bind alendronic acid and vomiting should not be inducedLabel. Patients may experience hypocalcemia, hypophosphatemia, and upper gastrointestinal events.Label.

There are currently no studies for safety and efficacy in pregnancy, though studies in pregnant rats show fetal and maternal complications at 4 times the clinical dose and pregnant rabbits do not show complications at as high as 10 times the clincal doseLabel.

Excretion in breast milk, and therefore safety in lactation, is unknownLabel.

Alendronic acid has been studied for use in pediatric patientsLabel. The oral bioavailability is similar to that in adult patients, but an increase in the portion of patients experiencing vomitingLabel.

There is no significant difference in efficacy or safety of alendronic acid in geriatric populations, though there is potential for even greater sensitivity in patients at a further advanced age than those in the studyLabel.

Alendronic acid is not recommended for patients with creatinine clearance <35mL/min, but no dosage adjustment is necessary in hepatic impairmentLabel.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Alendronate Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Alendronic acid.
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Alendronic acid.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alendronic acid.
AcipimoxThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Acipimox.
AcyclovirThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Acyclovir is combined with Alendronic acid.
Adefovir dipivoxilThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir dipivoxil is combined with Alendronic acid.
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Alendronic acid.
AlmasilateThe serum concentration of Alendronic acid can be decreased when it is combined with Almasilate.
AluminiumThe serum concentration of Alendronic acid can be decreased when it is combined with Aluminium.
Aluminium phosphateThe serum concentration of Alendronic acid can be decreased when it is combined with Aluminium phosphate.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Administer vitamin supplements. Patients may require supplemental vitamin D.
  • Avoid multivalent ions. Calcium, antacids, and divalent ions may interfere with the absorption of this medication.
  • Take before a meal. Take 30-60 minutes before breakfast.
  • Take with a full glass of water.

Products

Product Ingredients
IngredientUNIICASInChI Key
Alendronate calcium3JTA994BVH137504-90-6VFAZUESUCBECNE-UHFFFAOYSA-L
Alendronate sodium2UY4M2U3RA121268-17-5DCSBSVSZJRSITC-UHFFFAOYSA-M
Alendronate sodium anhydrous4988K7X26P129318-43-0CAKRAHQRJGUPIG-UHFFFAOYSA-M
Product Images
International/Other Brands
Alenotop (Pliva) / Alned (Laboratorios Belmac) / Arendal (Ivax) / Beenos (Gedeon Richter) / Berlex (Duncan) / Denfos (Biofarma) / Densidron (Mepha) / Dronat (Farmavita) / Durost (Perumed) / Fixopan (Grupo Farma) / Forosa (Kemofarmacija) / Fosagen (Aspen Pharmacare) / Fosalen (Teriak) / Fosmin (Hospimedikka) / Fostolin (Actavis) / Fosval (Saval) / Huesobone (Farmaceutica Latina) / Lendrate (Actavis) / Oseolen (Intipharma) / Ostemax (Polpharma)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Act AlendronateTabletOralActavis Pharma Company2005-06-142018-06-12Canada flag
Act AlendronateTabletOralActavis Pharma Company2005-06-142019-07-08Canada flag
AdrovanceTabletOralMerck Sharp & Dohme B.V.2007-01-04Not applicableEU flag
AdrovanceTabletOralMerck Sharp & Dohme B.V.2007-01-04Not applicableEU flag
AdrovanceTabletOralMerck Sharp & Dohme B.V.2007-01-04Not applicableEU flag
AdrovanceTabletOralMerck Sharp & Dohme B.V.2007-01-04Not applicableEU flag
AdrovanceTabletOralMerck Sharp & Dohme B.V.2007-01-04Not applicableEU flag
AdrovanceTabletOralMerck Sharp & Dohme B.V.2007-01-04Not applicableEU flag
AdrovanceTabletOralMerck Sharp & Dohme B.V.2007-01-04Not applicableEU flag
AlendronateTablet70 mgOralSorres Pharma Inc2009-02-262014-06-20Canada flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Accel-alendronateTabletOralAccel Pharma Inc2015-03-262017-09-13Canada flag
Accel-alendronateTabletOralAccel Pharma IncNot applicableNot applicableCanada flag
Accel-alendronateTabletOralAccel Pharma Inc2015-03-262017-09-13Canada flag
Ach-alendronateTabletOralAccord Healthcare Inc2012-03-20Not applicableCanada flag
Ach-alendronateTabletOralAccord Healthcare Inc2012-03-20Not applicableCanada flag
Ach-alendronateTabletOralAccord Healthcare Inc2012-03-20Not applicableCanada flag
Ag-alendronateTabletOralAngita Pharma Inc.Not applicableNot applicableCanada flag
Ag-alendronateTabletOralAngita Pharma Inc.Not applicableNot applicableCanada flag
Ag-alendronateTabletOralAngita Pharma Inc.Not applicableNot applicableCanada flag
AlendronateTablet70 mg/1OralNucare Pharmaceuticals,inc.2015-09-302019-12-31US flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Alendronate-cholecalciferolAlendronate sodium (70 mg) + Cholecalciferol (2800 unit)TabletOralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada flag
Alendronate-cholecalciferolAlendronate sodium (70 mg) + Cholecalciferol (5600 unit)TabletOralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada flag
Apo-alendronate/vitamin D3Alendronate sodium (70 mg) + Cholecalciferol (2800 unit)TabletOralApotex Corporation2016-07-21Not applicableCanada flag
Apo-alendronate/vitamin D3Alendronate sodium (70 mg) + Cholecalciferol (5600 unit)TabletOralApotex Corporation2016-07-21Not applicableCanada flag
Fosamax Plus DAlendronate sodium (70 mg/1) + Cholecalciferol (5600 [iU]/1)TabletOralMerck Sharp & Dohme Corp.2005-04-07Not applicableUS flag
Fosamax Plus DAlendronate sodium (70 mg/1) + Cholecalciferol (2800 [iU]/1)TabletOralPhysicians Total Care, Inc.2005-11-30Not applicableUS flag
Fosamax Plus DAlendronate sodium (70 mg/1) + Cholecalciferol (2800 [iU]/1)TabletOralMerck Sharp & Dohme Corp.2005-04-07Not applicableUS flag
FosavanceAlendronic acid (70 mg) + Cholecalciferol (2800 IU)TabletOralMerck Sharp & Dohme B.V.2005-08-24Not applicableEU flag
FosavanceAlendronic acid (70 mg) + Cholecalciferol (5600 IU)TabletOralMerck Sharp & Dohme B.V.2005-08-24Not applicableEU flag
FosavanceAlendronate sodium (70 mg) + Cholecalciferol (2800 unit)TabletOralMerck Ltd.2006-03-13Not applicableCanada flag

Categories

ATC Codes
M05BB03 — Alendronic acid and colecalciferolM05BA04 — Alendronic acidM05BB06 — Alendronic acid and alfacalcidol, sequentialM05BB05 — Alendronic acid, calcium and colecalciferol, sequential
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic phosphonic acids and derivatives
Sub Class
Bisphosphonates
Direct Parent
Bisphosphonates
Alternative Parents
Organic phosphonic acids / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives
Substituents
Aliphatic acyclic compound / Amine / Bisphosphonate / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organophosphonic acid
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
primary amino compound, 1,1-bis(phosphonic acid) (CHEBI:2567)

Chemical Identifiers

UNII
X1J18R4W8P
CAS number
66376-36-1
InChI Key
OGSPWJRAVKPPFI-UHFFFAOYSA-N
InChI
InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)
IUPAC Name
(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
SMILES
NCCCC(O)(P(O)(O)=O)P(O)(O)=O

References

Synthesis Reference

Masahiko Dohi, Yuji Makino, Takao Hujii, "Sodium alendronate preparation for local administration." U.S. Patent US5958908, issued September, 1997.

US5958908
General References
  1. Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8. [PubMed:18214569]
  2. Porras AG, Holland SD, Gertz BJ: Pharmacokinetics of alendronate. Clin Pharmacokinet. 1999 May;36(5):315-28. doi: 10.2165/00003088-199936050-00002. [PubMed:10384857]
  3. Lin JH, Chen IW, Deluna FA, Hichens M: Renal handling of alendronate in rats. An uncharacterized renal transport system. Drug Metab Dispos. 1992 Jul-Aug;20(4):608-13. [PubMed:1356743]
  4. Lin JH, Chen IW, deLuna FA, Hichens M: Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats. J Pharmacol Exp Ther. 1993 Nov;267(2):670-5. [PubMed:8246140]
  5. Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG: Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019 Jun;85(6):1052-1062. doi: 10.1111/bcp.13867. Epub 2019 Feb 28. [PubMed:30650219]
  6. FDA Approved Drugs: Alendronate [Link]
Human Metabolome Database
HMDB0001915
KEGG Compound
C07752
PubChem Compound
2088
PubChem Substance
46507199
ChemSpider
2004
BindingDB
25313
RxNav
236083
ChEBI
2567
ChEMBL
CHEMBL870
ZINC
ZINC000003801919
Therapeutic Targets Database
DAP000182
PharmGKB
PA448082
PDBe Ligand
212
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Alendronate
AHFS Codes
  • 92:24.00 — Bone Resorption Inhibitors
PDB Entries
5dz2
FDA label
Download (383 KB)
MSDS
Download (24.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionArteriosclerosis / Calcifications, Vascular1
4CompletedPreventionCystic Fibrosis (CF) / Muscular Dystrophy / Osteoporosis1
4CompletedPreventionOsteopenia / Osteoporosis1
4CompletedTreatmentBone Diseases, Metabolic / Cystic Fibrosis (CF) / Osteoporosis1
4CompletedTreatmentBone Resorption / Periodontitis1
4CompletedTreatmentCardiorenal Syndrome / Chronic Allograft Nephropathy (CAN)1
4CompletedTreatmentDepression / Healthy Volunteers / Osteopenia / Osteoporosis1
4CompletedTreatmentEnd Stage Renal Disease (ESRD) / Osteoporosis1
4CompletedTreatmentIntrabony Periodontal Defect1
4CompletedTreatmentOsteogenesis Imperfecta (OI)1

Pharmacoeconomics

Manufacturers
  • Merck and co inc
  • Apotex inc
  • Aurobindo pharma ltd
  • Austarpharma llc
  • Barr laboratories inc
  • Cadista pharmaceuticals inc
  • Dr reddys laboratories ltd
  • Genpharm ulc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Sun pharma global inc
  • Teva pharmaceuticals usa
  • Watson laboratories
  • Watson laboratories inc
Packagers
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Arrow Pharm Malta Ltd.
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • Barr Pharmaceuticals
  • Cipla Ltd.
  • Cobalt Pharmaceuticals Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • Lake Erie Medical and Surgical Supply
  • Merck & Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Northstar Rx LLC
  • Nucare Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Rebel Distributors Corp.
  • Southwood Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Watson Pharmaceuticals
Dosage Forms
FormRouteStrength
Tablet, coatedOral70 MG
Tablet35 mg
Tablet5 mg
TabletOral
Tablet, effervescent70 mg
Tablet70 MG
Tablet10 MG
Tablet, coatedOral150 mg
TabletOral10 mg/1
TabletOral40 mg/1
TabletOral70 mg/1
TabletOral91.35 mg
Tablet, film coatedOral70 MG
Tablet70 MG/2800IE
Tablet70 MG/5600IE
TabletOral5 MG
Tablet
Tablet, effervescentOral70 mg/1
Tablet, effervescentOral70 MG
SolutionOral70 MG
Tablet, film coated70 mg
Tablet, effervescentOral
SolutionOral70 mg/75mL
TabletOral35 mg/1
TabletOral40 mg
TabletOral5 mg/1
Tablet, coatedOral10 mg/1
TabletOral
TabletOral10 MG
Capsule, liquid filledOral70 mg
Tablet, delayed releaseOral5 mg
TabletOral70 mg
Tablet, effervescentOral12 mg
Prices
Unit descriptionCostUnit
Fosamax Plus D 4 70-2800 mg-Unit tablet Disp Pack107.66USD disp
Fosamax Plus D 4 70-5600 mg-Unit tablet Disp Pack107.66USD disp
Fosamax 1 Package = 4 tablet (70 mg) Package101.96USD package
Fosamax 1 Package = 4 tablet (35 mg) Package97.2USD package
Alendronate Sodium 4 35 mg tablet Package85.23USD package
Alendronate Sodium 4 70 mg tablet Package85.23USD package
Fosamax 70 mg/75ml Solution 75ml Bottle34.75USD bottle
Fosamax plus d 70 mg-5600 iu25.88USD each
Fosamax 70 mg tablet24.51USD tablet
Fosamax 35 mg tablet23.36USD tablet
Fosamax plus d 70 mg-2800 iu21.85USD each
Alendronate sodium 35 mg tablet20.49USD tablet
Alendronate sodium 70 mg tablet20.49USD tablet
Fosamax 40 mg tablet7.52USD tablet
Alendronate sodium 40 mg tablet6.73USD tablet
Fosamax 5 mg tablet3.4USD tablet
Fosamax 10 mg tablet3.4USD tablet
Alendronate sodium 10 mg tablet2.99USD tablet
Alendronate sodium 5 mg tablet2.99USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5358941No1994-10-252012-12-02US flag
CA2190148No2006-02-142015-05-12Canada flag
CA2294595No2001-08-212018-07-17Canada flag
US5994329Yes1999-11-302019-01-17US flag
US6015801Yes2000-01-182019-01-17US flag
US6225294Yes2001-05-012019-01-17US flag
US7964212No2011-06-212023-03-06US flag
US7488496No2009-02-102023-08-11US flag
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)235https://www.tcichemicals.com/eshop/en/us/commodity/A2120/
pKa2.72 (at 25 °C)MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility16.9 mg/mLALOGPS
logP-1.3ALOGPS
logP-4.2ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)0.69ChemAxon
pKa (Strongest Basic)9.91ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area161.31 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity47.37 m3·mol-1ChemAxon
Polarizability19.4 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.9554
Blood Brain Barrier+0.7065
Caco-2 permeable-0.7079
P-glycoprotein substrateNon-substrate0.6606
P-glycoprotein inhibitor INon-inhibitor0.947
P-glycoprotein inhibitor IINon-inhibitor0.9894
Renal organic cation transporterNon-inhibitor0.9205
CYP450 2C9 substrateNon-substrate0.8536
CYP450 2D6 substrateNon-substrate0.7997
CYP450 3A4 substrateNon-substrate0.6792
CYP450 1A2 substrateNon-inhibitor0.7567
CYP450 2C9 inhibitorNon-inhibitor0.9089
CYP450 2D6 inhibitorNon-inhibitor0.9344
CYP450 2C19 inhibitorNon-inhibitor0.9091
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9914
Ames testNon AMES toxic0.7079
CarcinogenicityNon-carcinogens0.7783
BiodegradationReady biodegradable0.6547
Rat acute toxicity1.6956 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8571
hERG inhibition (predictor II)Non-inhibitor0.8929
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-014i-2930000000-99692afb4ed253251947
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-001i-0900000000-d2c07307d66e1c7d52e8
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-0kdl-9500000000-c82a6e6e898154627c7d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Poly(a) rna binding
Specific Function
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids...
Gene Name
FDPS
Uniprot ID
P14324
Uniprot Name
Farnesyl pyrophosphate synthase
Molecular Weight
48275.03 Da
References
  1. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41. [PubMed:10620343]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [PubMed:11160603]
  4. Guo RT, Cao R, Liang PH, Ko TP, Chang TH, Hudock MP, Jeng WY, Chen CK, Zhang Y, Song Y, Kuo CJ, Yin F, Oldfield E, Wang AH: Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7. Epub 2007 May 29. [PubMed:17535895]
Kind
Small molecule
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
References
  1. Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [PubMed:20209564]
  2. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [PubMed:16046206]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Non-membrane spanning protein tyrosine phosphatase activity
Specific Function
May act at junctions between the membrane and the cytoskeleton.
Gene Name
PTPN4
Uniprot ID
P29074
Uniprot Name
Tyrosine-protein phosphatase non-receptor type 4
Molecular Weight
105910.315 Da
References
  1. Opas EE, Rutledge SJ, Golub E, Stern A, Zimolo Z, Rodan GA, Schmidt A: Alendronate inhibition of protein-tyrosine-phosphatase-meg1. Biochem Pharmacol. 1997 Sep 15;54(6):721-7. [PubMed:9310349]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transmembrane receptor protein tyrosine phosphatase activity
Specific Function
Interacts with LAR-interacting protein LIP.1.
Gene Name
PTPRS
Uniprot ID
Q13332
Uniprot Name
Receptor-type tyrosine-protein phosphatase S
Molecular Weight
217039.825 Da
References
  1. Opas EE, Rutledge SJ, Golub E, Stern A, Zimolo Z, Rodan GA, Schmidt A: Alendronate inhibition of protein-tyrosine-phosphatase-meg1. Biochem Pharmacol. 1997 Sep 15;54(6):721-7. [PubMed:9310349]
  2. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA: Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3068-73. [PubMed:8610169]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transmembrane receptor protein tyrosine phosphatase activity
Specific Function
Isoform 1 plays a critical role in signaling transduction pathways and phosphoprotein network topology in red blood cells. May play a role in osteoclast formation and function (By similarity).Isofo...
Gene Name
PTPRE
Uniprot ID
P23469
Uniprot Name
Receptor-type tyrosine-protein phosphatase epsilon
Molecular Weight
80641.165 Da
References
  1. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA: Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3068-73. [PubMed:8610169]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Proton-transporting atpase activity, rotational mechanism
Specific Function
Catalytic subunit of the peripheral V1 complex of vacuolar ATPase. V-ATPase vacuolar ATPase is responsible for acidifying a variety of intracellular compartments in eukaryotic cells.
Gene Name
ATP6V1A
Uniprot ID
P38606
Uniprot Name
V-type proton ATPase catalytic subunit A
Molecular Weight
68303.5 Da
References
  1. David P, Nguyen H, Barbier A, Baron R: The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J Bone Miner Res. 1996 Oct;11(10):1498-507. [PubMed:8889850]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2020 01:55

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates